Diebold Nixdorf, Incorporated
DBD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $4 | $3 | $4 |
| % Growth | -0.2% | 8.7% | -11.4% | – |
| Cost of Goods Sold | $3 | $3 | $3 | $3 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 24.5% | 23.3% | 21.9% | 26.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $0 | $0 | -$0 | $0 |
| % Margin | 4.9% | 2.3% | -6.1% | 3.5% |
| Other Income/Exp. Net | -$0 | $1 | -$0 | -$0 |
| Pre-Tax Income | $0 | $1 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $1 | -$1 | -$0 |
| % Margin | -0.4% | 36.6% | -16.8% | -2% |
| EPS | -0.44 | 21.38 | -7.44 | -1 |
| % Growth | -102.1% | 387.4% | -644% | – |
| EPS Diluted | -0.44 | 21.38 | -7.44 | -1 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 8.9% | 7.3% | -3.3% | 7.5% |